166 related articles for article (PubMed ID: 30830412)
1. Insights into gemcitabine resistance and the potential for therapeutic monitoring.
Gebregiworgis T; Bhinderwala F; Purohit V; Chaika NV; Singh PK; Powers R
Metabolomics; 2018 Nov; 14(12):156. PubMed ID: 30830412
[TBL] [Abstract][Full Text] [Related]
2. Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells.
Fujimura Y; Ikenaga N; Ohuchida K; Setoyama D; Irie M; Miura D; Wariishi H; Murata M; Mizumoto K; Hashizume M; Tanaka M
Pancreas; 2014 Mar; 43(2):311-8. PubMed ID: 24518513
[TBL] [Abstract][Full Text] [Related]
3. Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells.
Suenaga S; Kuramitsu Y; Wang Y; Baron B; Kitagawa T; Akada J; Tokuda K; Kaino S; Maehara S; Maehara Y; Sakaida I; Nakamura K
Anticancer Res; 2013 Nov; 33(11):4821-6. PubMed ID: 24222118
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
Wang R; Cheng L; Xia J; Wang Z; Wu Q; Wang Z
Curr Cancer Drug Targets; 2014; 14(4):407-17. PubMed ID: 24575976
[TBL] [Abstract][Full Text] [Related]
6. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
[TBL] [Abstract][Full Text] [Related]
7. Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells.
Kang D; Choi HJ; Kang S; Kim SY; Hwang YS; Je S; Han Z; Kim JH; Song JJ
Cell Signal; 2015 Apr; 27(4):807-17. PubMed ID: 25615626
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.
de Sousa Cavalcante L; Monteiro G
Eur J Pharmacol; 2014 Oct; 741():8-16. PubMed ID: 25084222
[TBL] [Abstract][Full Text] [Related]
9.
Tadros S; Shukla SK; King RJ; Gunda V; Vernucci E; Abrego J; Chaika NV; Yu F; Lazenby AJ; Berim L; Grem J; Sasson AR; Singh PK
Cancer Res; 2017 Oct; 77(20):5503-5517. PubMed ID: 28811332
[TBL] [Abstract][Full Text] [Related]
10. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
Minami K; Shinsato Y; Yamamoto M; Takahashi H; Zhang S; Nishizawa Y; Tabata S; Ikeda R; Kawahara K; Tsujikawa K; Chijiiwa K; Yamada K; Akiyama S; Pérez-Torras S; Pastor-Anglada M; Furukawa T; Yasuo T
J Pharmacol Sci; 2015 Mar; 127(3):319-25. PubMed ID: 25837929
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway.
Yu C; Chen S; Guo Y; Sun C
Theranostics; 2018; 8(12):3224-3236. PubMed ID: 29930725
[No Abstract] [Full Text] [Related]
12. Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer.
Kim YJ; Hong YB; Cho CH; Seong YS; Bae I
Pancreas; 2012 Jul; 41(5):804-5. PubMed ID: 22695089
[No Abstract] [Full Text] [Related]
13. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
Samulitis BK; Pond KW; Pond E; Cress AE; Patel H; Wisner L; Patel C; Dorr RT; Landowski TH
Cancer Biol Ther; 2015; 16(1):43-51. PubMed ID: 25485960
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
Xiong G; Liu C; Yang G; Feng M; Xu J; Zhao F; You L; Zhou L; Zheng L; Hu Y; Wang X; Zhang T; Zhao Y
J Hematol Oncol; 2019 Sep; 12(1):97. PubMed ID: 31514732
[TBL] [Abstract][Full Text] [Related]
15. Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells.
Taba K; Kuramitsu Y; Ryozawa S; Yoshida K; Tanaka T; Maehara S; Maehara Y; Sakaida I; Nakamura K
Anticancer Res; 2010 Jul; 30(7):2539-43. PubMed ID: 20682980
[TBL] [Abstract][Full Text] [Related]
16. [Establish a gemcitabine-resistant pancreatic cancer cell line SW1990/GZ and research the relationship between SW1990/GZ and pancreatic cancer stem cell].
An Y; Yao J; Wei JS; Lu ZP; Cai HH; Dai CC; Qian ZY; Xu ZK; Miao Y
Zhonghua Wai Ke Za Zhi; 2010 Jul; 48(13):999-1003. PubMed ID: 21054984
[TBL] [Abstract][Full Text] [Related]
17. Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer.
Liu QH; Zhang J; Zhao CY; Yu DH; Bu HJ; Chen Y; Ni CY; Zhu MH
Cancer Lett; 2012 Jan; 314(1):119-25. PubMed ID: 21983131
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells.
Funamizu N; Lacy CR; Kamada M; Yanaga K; Manome Y
Int J Oncol; 2019 Mar; 54(3):991-1000. PubMed ID: 30628651
[TBL] [Abstract][Full Text] [Related]
19. Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine.
Suenaga S; Kuramitsu Y; Kaino S; Maehara S; Maehara Y; Sakaida I; Nakamura K
Anticancer Res; 2014 Jan; 34(1):141-6. PubMed ID: 24403454
[TBL] [Abstract][Full Text] [Related]
20. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer.
Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake M; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Wangsiricharoen S; Bouvet M; Singh SR; Unno M; Hoffman RM
Cancer Lett; 2018 Sep; 432():251-259. PubMed ID: 29928962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
